🇺🇸 LLY — Eli Lilly and Company

Salud Compra
← Volver

Precio actual

1.417,99 USD

Máx. histórico

1.417,99

0 días

Split 2:1 del 16/10/1997

Caída desde máximo

En máximo

Rango 52 semanas

850,51 – 1.449,68

Variación hoy

+0,61%

Cierre anterior

1.409,38

Rango de hoy

1.401,59 – 1.445,96

Volumen hoy

3.622.682

Peor caída histórica

-68,26%

08/08/2000 → 05/03/2009

Recuperado en 2064 días

Volatilidad anualizada ⓘ

27,61%

Información
Nombre completo
Eli Lilly and Company
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Drug Manufacturers - General
Empleados
50.000
PER ⓘ
46,02 (puede no estar actualizado)
Dividend yield
0,49% (puede no estar actualizado)
Precio objetivo analistas
1.442,09 USD (puede no estar actualizado)
Primera cotización
01/06/1972
Precio actualizado
hace 3 horas
Sobre la empresa

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Dividendos repartidos Total últimos 12 meses: 6,6900 USD · Yield: 0,47%
Fecha de pago Importe por participación
14/08/2026 1,7300 USD
15/05/2026 1,7300 USD
13/02/2026 1,7300 USD
14/11/2025 1,5000 USD
15/08/2025 1,5000 USD
16/05/2025 1,5000 USD
14/02/2025 1,5000 USD
15/11/2024 1,3000 USD
15/08/2024 1,3000 USD
15/05/2024 1,3000 USD
14/02/2024 1,3000 USD
14/11/2023 1,1300 USD
14/08/2023 1,1300 USD
12/05/2023 1,1300 USD
14/02/2023 1,1300 USD
Splits Registrados en el histórico de precios
Fecha Ratio
16/10/1997 2:1
21/12/1995 2:1
01/05/1989 2:1
30/01/1986 2:1
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
13/04/2020 144,97 146,59 142,88 144,42 -0,90% 2,56% 2.289.000
09/04/2020 144,51 146,40 143,55 145,73 -0,34% 1,97% 4.415.300
08/04/2020 142,05 147,25 140,50 146,22 +3,06% 4,75% 4.006.600
07/04/2020 143,13 144,80 140,05 141,88 +0,19% 3,32% 3.900.600
06/04/2020 142,27 143,50 140,30 141,61 +1,40% 2,25% 4.159.900
03/04/2020 140,92 144,60 138,46 139,66 -1,77% 4,36% 4.013.200
02/04/2020 135,35 142,80 133,03 142,18 +4,22% 7,22% 4.725.000
01/04/2020 134,00 137,19 132,98 136,42 -1,66% 3,14% 3.297.900
31/03/2020 136,96 142,02 134,52 138,72 +0,20% 5,48% 7.560.100
30/03/2020 133,87 141,77 133,51 138,44 +3,23% 6,17% 5.057.400
27/03/2020 130,65 137,61 130,20 134,11 -0,18% 5,67% 4.717.400
26/03/2020 123,29 135,74 121,94 134,35 +10,18% 11,19% 6.723.600
25/03/2020 120,12 126,14 119,21 121,94 -0,77% 5,77% 6.472.100
24/03/2020 123,24 124,60 117,41 122,89 +3,23% 5,83% 6.827.300
23/03/2020 120,95 126,88 117,06 119,05 -2,74% 8,12% 7.299.300
20/03/2020 132,16 132,25 120,23 122,40 -8,03% 9,10% 9.113.500
19/03/2020 142,49 142,98 131,12 133,09 -6,99% 8,32% 6.554.800
18/03/2020 136,34 144,00 134,08 143,09 -0,08% 7,28% 6.734.600
17/03/2020 133,21 143,59 131,10 143,20 +10,68% 9,38% 8.909.200
16/03/2020 131,00 138,68 128,25 129,38 -7,17% 7,96% 6.619.700
13/03/2020 132,95 139,37 128,51 139,37 +10,59% 8,17% 6.841.700
12/03/2020 130,79 136,50 125,93 126,02 -10,00% 8,08% 7.836.300
11/03/2020 139,46 141,84 137,39 140,02 -0,83% 3,19% 7.211.800
10/03/2020 139,23 141,93 134,72 141,19 +4,03% 5,18% 5.961.200
09/03/2020 134,02 140,93 133,31 135,72 -4,06% 5,69% 5.351.300
06/03/2020 136,12 142,36 135,55 141,46 +0,93% 5,00% 8.010.700
05/03/2020 138,38 141,91 137,53 140,15 -0,16% 3,17% 6.882.100
04/03/2020 133,03 140,86 133,00 140,38 +7,73% 5,91% 5.301.900
03/03/2020 133,28 135,65 128,69 130,31 -1,90% 5,22% 6.936.600
02/03/2020 127,74 133,00 126,21 132,84 +5,32% 5,32% 7.355.700